425 related articles for article (PubMed ID: 18403404)
1. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.
Riley P; McCann LJ; Maillard SM; Woo P; Murray KJ; Pilkington CA
Rheumatology (Oxford); 2008 Jun; 47(6):877-80. PubMed ID: 18403404
[TBL] [Abstract][Full Text] [Related]
2. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.
Dastmalchi M; Grundtman C; Alexanderson H; Mavragani CP; Einarsdottir H; Helmers SB; Elvin K; Crow MK; Nennesmo I; Lundberg IE
Ann Rheum Dis; 2008 Dec; 67(12):1670-7. PubMed ID: 18272672
[TBL] [Abstract][Full Text] [Related]
3. A follow-up study in 28 patients treated with infliximab for severe recalcitrant psoriasis: evidence for efficacy and high incidence of biological autoimmunity.
Poulalhon N; Begon E; Lebbé C; Lioté F; Lahfa M; Bengoufa D; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2007 Feb; 156(2):329-36. PubMed ID: 17223874
[TBL] [Abstract][Full Text] [Related]
4. Infliximab for the treatment of refractory progressive sterile peripheral ulcerative keratitis associated with late corneal perforation: 3-year follow-up.
Odorcic S; Keystone EC; Ma JJ
Cornea; 2009 Jan; 28(1):89-92. PubMed ID: 19092414
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of infliximab and adalimumab treatment in a large cohort of juvenile dermatomyositis patients.
Campanilho-Marques R; Deakin CT; Simou S; Papadopoulou C; Wedderburn LR; Pilkington CA;
Arthritis Res Ther; 2020 Apr; 22(1):79. PubMed ID: 32293539
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis.
Nakamura H; Kawakami A; Ida H; Ejima E; Origuchi T; Eguchi K
J Rheumatol; 2006 Aug; 33(8):1691-3. PubMed ID: 16881125
[TBL] [Abstract][Full Text] [Related]
7. Oropharyngeal dysphagia in juvenile dermatomyositis (JDM): an evaluation of videofluoroscopy swallow study (VFSS) changes in relation to clinical symptoms and objective muscle scores.
McCann LJ; Garay SM; Ryan MM; Harris R; Riley P; Pilkington CA
Rheumatology (Oxford); 2007 Aug; 46(8):1363-6. PubMed ID: 17569746
[TBL] [Abstract][Full Text] [Related]
8. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety.
Riley P; Maillard SM; Wedderburn LR; Woo P; Murray KJ; Pilkington CA
Rheumatology (Oxford); 2004 Apr; 43(4):491-6. PubMed ID: 14722349
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of infliximab in active SLE: a pilot study.
Uppal SS; Hayat SJ; Raghupathy R
Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
[TBL] [Abstract][Full Text] [Related]
10. Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis.
Simonini G; Zannin ME; Caputo R; Falcini F; de Martino M; Zulian F; Cimaz R
Rheumatology (Oxford); 2008 Oct; 47(10):1510-4. PubMed ID: 18676502
[TBL] [Abstract][Full Text] [Related]
11. Infliximab in severe active ankylosing spondylitis with spinal ankylosis.
Cheung PP; Tymms KE; Wilson BJ; Shadbolt B; Brook AS; Dorai Raj AK; Khoo KB
Intern Med J; 2008 Jun; 38(6):396-401. PubMed ID: 18336538
[TBL] [Abstract][Full Text] [Related]
12. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis.
Marhaug G; Shah V; Shroff R; Varsani H; Wedderburn LR; Pilkington CA; Brogan PA
Rheumatology (Oxford); 2008 Jul; 47(7):1031-7. PubMed ID: 18448482
[TBL] [Abstract][Full Text] [Related]
13. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade.
Winterfield L; Menter A
Dermatol Clin; 2004 Oct; 22(4):437-47, ix. PubMed ID: 15450339
[TBL] [Abstract][Full Text] [Related]
14. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.
Huber AM; Lang B; LeBlanc CM; Birdi N; Bolaria RK; Malleson P; MacNeil I; Momy JA; Avery G; Feldman BM
Arthritis Rheum; 2000 Mar; 43(3):541-9. PubMed ID: 10728746
[TBL] [Abstract][Full Text] [Related]
15. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients.
Josselin L; Mahr A; Cohen P; Pagnoux C; Guaydier-Souquières G; Hayem G; Job-Deslandre C; Liferman F; Pourrat J; Guillevin L
Ann Rheum Dis; 2008 Sep; 67(9):1343-6. PubMed ID: 18445626
[TBL] [Abstract][Full Text] [Related]
16. The arthritis of inflammatory childhood myositis syndromes.
Tse S; Lubelsky S; Gordon M; Al Mayouf SM; Babyn PS; Laxer RM; Silverman ED; Schneider R; Feldman BM
J Rheumatol; 2001 Jan; 28(1):192-7. PubMed ID: 11196524
[TBL] [Abstract][Full Text] [Related]
17. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
Denton CP; Engelhart M; Tvede N; Wilson H; Khan K; Shiwen X; Carreira PE; Diaz Gonzalez F; Black CM; van den Hoogen FH
Ann Rheum Dis; 2009 Sep; 68(9):1433-9. PubMed ID: 18782794
[TBL] [Abstract][Full Text] [Related]
18. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of a single course of infliximab in hidradenitis suppurativa.
Mekkes JR; Bos JD
Br J Dermatol; 2008 Feb; 158(2):370-4. PubMed ID: 18047504
[TBL] [Abstract][Full Text] [Related]
20. [Infectious risk].
Calabuig E; Salavert M
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():14-22. PubMed ID: 19080987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
